Protriptyline

3 - ( 5H- dibenzo [a, d ] annulene -5-yl )-N- methylpropan - 1-amine

  • 438-60-8
  • 1225-55-4 ( protriptyline · hydrochloride)

N06AA11

Antidepressant

Hydrochloride

Risk

  • 240 mg · kg -1 ( LD50, rat, oral)
  • 67 mg · kg -1 ( LD50, mouse, ip)

Template: Infobox chemical / molecular formula search available

Protriptyline (trade name: Vivactil ®, Concordin ®) is a drug from the group of tricyclic antidepressants. It inhibits similarly strong as desipramine the resumption of the neurotransmitter noradrenaline, without having any appreciable sedative properties. Protriptyline also acts as FIASMA ( functional inhibitors of acid sphingomyelinase ).

Clinical information

Areas of application (indications )

The drug is its mechanism of action mentioned above particularly well suited for the treatment of depression with a distinct lack of drive. Treatment success can also ADHD, narcolepsy and chronic pain syndrome can be achieved.

Adverse effects (side effects)

When protriptyline include the following adverse effects are observed:

  • Moderate to strong: effects on cardiac function
  • Default: anticholinergic effects and epileptic seizures
  • Low: low blood pressure ( hypotension) and weight gain
  • Minimal: sedation

Dosage

The usual daily dose is between 15 and 40 mg doses, the extreme between 10 and 60 mg per day.

Pharmacological properties

The plasma elimination half -life of the drug is 54 bis 198 hours relatively long.

CAS registry number PubChem Anatomical Therapeutic Chemical Classification System DrugBank Dangerous Substances Directive (67/548/EEC) Intraperitoneal injection Active ingredient Major depressive disorder Digital Object Identifier
662867
de